Published December 26, 2012 | Version v1
Journal article

The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism

  • 1. Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai (Japan)
  • 2. Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai (Japan)
  • 3. Center for Regulatory Epigenome and Diseases, Tohoku University Graduate School of Medicine, Sendai (Japan)
  • 4. Center for Radioisotope Sciences, Tohoku University Graduate School of Medicine, Sendai (Japan)

Description

The Keap1–Nrf2 [Kelch-like ECH-associated protein 1–nuclear factor (erythroid-derived 2)-like 2] pathway plays a central role in the protection of cells against oxidative and xenobiotic stresses. Nrf2 is a potent transcription activator that recognizes a unique DNA sequence known as the antioxidant response element (ARE). Under normal conditions, Nrf2 binds to Keap1 in the cytoplasm, resulting in proteasomal degradation. Following exposure to electrophiles or reactive oxygen species, Nrf2 becomes stabilized, translocates into the nucleus, and activates the transcription of various cytoprotective genes. Increasing attention has been paid to the role of Nrf2 in cancer cells because the constitutive stabilization of Nrf2 has been observed in many human cancers with poor prognosis. Recent studies have shown that the antioxidant and detoxification activities of Nrf2 confer chemo- and radio-resistance to cancer cells. In this review, we provide an overview of the Keap1–Nrf2 system and discuss its role under physiological and pathological conditions, including cancers. We also introduce the results of our recent study describing Nrf2 function in the metabolism of cancer cells. Nrf2 likely confers a growth advantage to cancer cells through enhancing cytoprotection and anabolism. Finally, we discuss the possible impact of Nrf2 inhibitors on cancer therapy.

Availability note (English)

Available from http://dx.doi.org/10.3389/fonc.2012.00200

Additional details

Identifiers

Publishing Information

Journal Title
Frontiers in Oncology
Journal Volume
2
Journal Page Range
[13 p.]
ISSN
2234-943X

INIS

Country of Publication
Switzerland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
49037115
Subject category
S60: APPLIED LIFE SCIENCES; S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ANABOLISM; BIOLOGICAL STRESS; GLUTATHIONE; NEOPLASMS; TRANSCRIPTION
Descriptors DEC
DISEASES; DRUGS; METABOLISM; ORGANIC COMPOUNDS; PEPTIDES; POLYPEPTIDES; PROTEINS; RADIOPROTECTIVE SUBSTANCES; RESPONSE MODIFYING FACTORS

Optional Information

Copyright
Copyright (c) Mitsuishi, Motohashi and Yamamoto.